CN111202238A - 一种具有降血脂功能的保健品 - Google Patents
一种具有降血脂功能的保健品 Download PDFInfo
- Publication number
- CN111202238A CN111202238A CN201811401287.3A CN201811401287A CN111202238A CN 111202238 A CN111202238 A CN 111202238A CN 201811401287 A CN201811401287 A CN 201811401287A CN 111202238 A CN111202238 A CN 111202238A
- Authority
- CN
- China
- Prior art keywords
- blood fat
- health
- health product
- weight
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 24
- 239000008280 blood Substances 0.000 title claims abstract description 24
- 230000036541 health Effects 0.000 title claims abstract description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 229960003080 taurine Drugs 0.000 claims abstract description 11
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 6
- 239000011651 chromium Substances 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 229940107218 chromium Drugs 0.000 claims description 3
- 229940076130 chromium gluconate Drugs 0.000 claims description 3
- 229940046374 chromium picolinate Drugs 0.000 claims description 3
- ANPGUZATXCGJJH-OPDGVEILSA-K chromium(3+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O ANPGUZATXCGJJH-OPDGVEILSA-K 0.000 claims description 3
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical group [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims description 3
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 claims description 3
- 229930014626 natural product Natural products 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 206010012735 Diarrhoea Diseases 0.000 abstract description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000284 extract Substances 0.000 abstract description 4
- 235000010413 sodium alginate Nutrition 0.000 abstract description 4
- 239000000661 sodium alginate Substances 0.000 abstract description 4
- 229940005550 sodium alginate Drugs 0.000 abstract description 4
- 235000010418 carrageenan Nutrition 0.000 abstract description 3
- 239000000679 carrageenan Substances 0.000 abstract description 3
- 229920001525 carrageenan Polymers 0.000 abstract description 3
- 229940113118 carrageenan Drugs 0.000 abstract description 3
- 230000036186 satiety Effects 0.000 abstract description 3
- 235000019627 satiety Nutrition 0.000 abstract description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract description 3
- 235000021590 normal diet Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000003925 fat Substances 0.000 description 29
- 235000019197 fats Nutrition 0.000 description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- 235000013305 food Nutrition 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 231100000987 absorbed dose Toxicity 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有降血脂功能的保健品，由下述重量百分数含量的原料制成的：卡拉胶15～75％，牛磺酸10～70％，海藻酸钠10～70％，有机三价铬0.01～0.50％。本发明保健品选用纯天然海洋生物提取物为主要原料，功效成份明确，组分少，天然无毒副作用。不影响正常饮食，具有明显的饱腹感，不会发生腹泻，降血脂效果明显。
Description
技术领域
本发明涉及一种具有降血脂功能的保健品，尤其涉及一种以海洋生物提取物为主要原料制备的具有降血脂功能的保健品。
背景技术
肥胖还可引起一系列激素与代谢紊乱，各种危险因素协同作用，直接或间接对血脂代谢产生不良影响。大量流行病学研究表明，单纯肥胖者人群平均血清甘油三脂(TG)、总胆固醇(TC)水平显著高于年龄、性别构成相似的非超重者。还有报道，单纯肥胖者中约近半数人发生血清TG增高，且发生率与肥胖程度正相关。几乎所有流行病学研究，无论对男性或女性，对老人或青年，皆证明肥胖多倾向于有较低水平的血清高密度脂蛋白胆固醇(HDL-C)。肥胖者血清TG水平升高，HDL-C水平下降，可能与体重增加时，肝内HDL-C被转移去运载极低密度脂蛋白胆固醇(VLDL-C)中的TG，因此血清TG水平升高同时伴有血清HDL-C水平降低有关。高脂血症与动脉硬化有着密切的联系，而动脉粥样硬化会导致高血压、冠心病、脑出血、脑栓塞，是威胁人群最重要的死亡原因之一。
国内外流行病学和临床研究均已证明，超重或肥胖者在体重减轻后，血脂异常可得到恢复。总之，减重不仅改善脂质代谢，也是减少动脉粥样硬化(CHD)危险因素获益最多的干预措施。目前减肥的手段主要是采用腹泻减肥、替食抑食、调节膳食、能量代谢的传统减肥法，药物减肥效果快，但副作用太大，而且容易反弹。基于对安全的考虑，绝大多数肥胖症者都偏向食用安全性高的保健食品，关键的是要增加减肥保健食品的科技含量，提高其功效。现代医学研究证实，引起肥胖症是多种原因，肥胖主要与机体吸收葡萄糖、脂肪、胆固醇以及体内脂肪的积聚有关，肥胖与高血脂是相互存在、相互影响的关系。
目前国内外具有减肥功能的海洋功能食品很少，同时减肥和降血脂的海洋功能食品尚未见到。主要原因包括：(1)我国对海洋生物的药用性和食用性研究较晚，海洋生物活性物减肥和降血脂的独特功能尚未被人们普遍认识；(2)海洋生物活性物的分离提取技术和利用仍然是一门新地边缘学科；(3)有一些减肥和降脂保健食品生产不规范，也影响了对减肥和降血脂保健食品的科研投入和深层次的开发。
目前大多数减肥的保健食品是以中草药为原料，以腹泻减肥为主，通过腹泻、厌食来使体重下降。但是，过多的腹泻还会引起脱水，而且单纯腹泻的保健食品很容易反弹，更为重要的是长期腹泻有害于健康。也有一些以中药材为原料制成的以能量代谢为手段的减肥保健食品，是通过燃烧并排除体内多余脂肪来实现减肥，但以单一手段减轻体重不是科学有效的方法，因为从外来食物中摄入的脂类物质以及小肠壁上脂肪和胆固醇的合成，高血脂都会引起肥胖症。
发明内容
本发明的目的在于针对现有技术中的上述不足，提供一种具有降血脂功能的保健品。
本发明基于对肥胖症和高血脂的认识及原则，以及对海洋生物活性物的了解，参考现代医学和人体科学研究成就，从海洋生物提取物中筛选出具有很强的减肥和降血脂的海洋生物活性物，然后根据中医药理论，按其功效主次顺序排列而成，使其发挥人体机体抑制脂肪和胆固醇的生成，清血脂，延缓对葡萄糖、脂肪和胆固醇的消化吸收过程，增加生物活性，以达到安全、有效减肥和降脂的效果。
本发明提供的具有降血脂功能的保健品，是由下述重量百分数含量的原料制成的：
优选的，各原料的重量百分数含量为：
优选的，所述的牛磺酸是指从天然物提取的牛磺酸或人工合成的牛磺酸。
优选的，所述的有机三价铬是指在各种药品添加剂和保健食品营养素中所使用的吡啶甲酸铬、葡萄糖酸铬、铬酵母或烟酸铬。
优选的，保健品剂型是胶囊剂、片剂、散剂、冲剂、膏剂或颗粒剂。
与现有技术相比，本方案具有以下优点和技术效果：
卡拉胶是从海藻中分离提取出的硫酸酯半乳聚糖，它独特的化学性质和活性体现在：①能抑制胰脂肪酶的活性，阻止脂肪被分解为脂肪酸和β-单酸甘油酯而被吸收；②能抑制胆固醇酯酶的活性，阻止胆固醇被从食物中游离出来转化成酯型乳糜微粒而被吸收。从而减少机体对脂肪的合成及延缓机体对脂肪的吸收，降低胰脂肪酶和胆固醇酯酶合成脂质的活性，能有效预防和延缓肥胖症的发生。
牛磺酸可与胆汁酸结合形成牛黄胆酸，有利于消化道中脂类的吸收。牛磺酸的等电点较低，易在小肠溶解并与脂肪混合形成乳糜微粒而被吸收。牛黄胆酸是胆汁中的胆汁盐，它在小肠中作为去垢剂，有助于脂肪的溶解，这样脂肪就更容易被肠脂酶降解。起到降低血清胆固醇，升高血清高密度脂蛋白-胆固醇，防止动脉粥样硬化的作用。本发明所说的牛磺酸可以是从天然物提取的牛磺酸或人工合成的牛磺酸。
海藻酸钠有延缓或减少对葡萄糖、脂肪和胆固醇的消化和吸收的作用机制，首先是食物糊因摄入海藻酸钠后粘度上升，因而延长食物糊在胃内的滞留时间，其次是降低了小肠内葡萄糖的扩散速度，延缓了葡萄糖的消化吸收过程，它还可以通过缩短食糜在小肠内滞留；吸附胆汁酸，降低它对脂类的乳化、消化过程，阻抑脂质分子向小肠壁移动，从而收到浮肿减轻、体重下降的效果。
有机铬(III)参与动物体内糖、脂肪、蛋白质的代谢，可提高组织对葡萄糖的摄取与分解，提高肌肉及其它组织对氨基酸的摄取与蛋白质合成，调控组织中脂肪生成与分解，转化脂肪并增加肌肉，能有效促进减肥。有机铬(III)是指在各种药品添加剂和保健食品营养素中所使用的吡啶甲酸铬、葡萄糖酸铬、铬酵母或烟酸铬。
另外，控制食欲是有效减肥的基本措施，海藻酸盐和卡拉胶吸水膨胀后体积增大，在胃内产生明显的饱腹感，延缓胃内容物的排空，从而降低食欲，并且不影响体力。
本发明保健品选用纯天然海洋生物提取物为主要原料，功效成份明确，组分少，天然无毒副作用。不影响正常饮食，具有明显的饱腹感，不会发生腹泻。
具体实施方式
下面结合具体实施例对本发明进行详细的解释和说明，以使本领域技术人员更好地理解和实施本发明。
实施例1
本发明的海洋功能食品由下列重量百分数含量的原料制成：
将上述组分制成胶囊的生产方法是：(1)将上述原料干燥、粉碎至80目以上的细度；(2)将上述粉剂组分按比例混合后，按填充胶囊工序填充胶囊，装瓶，包装。使用伽玛射线辅照，进行灭菌、消毒，产品的实际吸收剂量为5.0KGY。
实施例2
本发明的海洋功能食品由下列重量百分数含量的原料制成：
将上述组分制成片剂的生产方法是：(1)将上述原料干燥、粉碎至80目以上的细度；(2)将上述粉剂组分按比例混合后，按压片制备工序制备片剂，装瓶，包装。使用伽玛射线辅照，进行灭菌、消毒，产品的实际吸收剂量为5.0KGY。
实施例3
本发明的海洋功能食品由下列重量百分数含量的原料制成：
将上述组分制成颗粒剂的生产方法是：(1)将原料干燥、粉碎至80目以上的细度；(2)将上述粉剂组分按比例混合后，按制备颗粒剂工序制备颗粒剂，装瓶，包装。使用伽玛射线辅照，进行灭菌、消毒，产品的实际吸收剂量为5.0KGY。
降血脂的动物功能试验结果：
对健康SPF级Wistar种大鼠每天给予高脂营养饲料，同时分别给予0.35、0.70、1.05g/kgBW本发明样品，为人体推荐量的5、10、15倍，试验共30天，结果显示：
1.受试样本发明样品降低大鼠血清TC水平，试验结果为阳性。
2.受试样本发明样品降低大鼠血清TG水平，试验结果为阳性。
3.受试样本发明样品对大鼠血清HDL-C水平无影响，试验结果为阴性。
根据上述结果，依据卫生部《保健食品检验与评价技术规范》中辅助降血脂功能判断，本发明对动物具有降血脂作用。
以上实施例的说明只是用于帮助理解本发明的核心思想，在不脱离该发明构思的前提下，所做的任何显而易见的修改、等同替换或其他改进，均应包含在本发明的保护范围之内。
Claims (5)
1.一种具有降血脂功能的保健品，其特征在于，它是由下述重量百分数含量的原料制成的：
2.根据权利要求1所述的具有降血脂功能的保健品，其中各原料的重量百分数含量为：
3.根据权利要求1所述的具有降血脂功能的保健品，其特征在于，所述的牛磺酸是指从天然物提取的牛磺酸或人工合成的牛磺酸。
4.根据权利要求1所述的具有降血脂功能的保健品，其特征在于，所述的有机三价铬是指在各种药品添加剂和保健食品营养素中所使用的吡啶甲酸铬、葡萄糖酸铬、铬酵母或烟酸铬。
5.根据权利要求1所述的具有降血脂功能的保健品，其特征在于，剂型是胶囊剂、片剂、散剂、冲剂、膏剂或颗粒剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811401287.3A CN111202238A (zh) | 2018-11-22 | 2018-11-22 | 一种具有降血脂功能的保健品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811401287.3A CN111202238A (zh) | 2018-11-22 | 2018-11-22 | 一种具有降血脂功能的保健品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111202238A true CN111202238A (zh) | 2020-05-29 |
Family
ID=70780281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811401287.3A Pending CN111202238A (zh) | 2018-11-22 | 2018-11-22 | 一种具有降血脂功能的保健品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111202238A (zh) |
-
2018
- 2018-11-22 CN CN201811401287.3A patent/CN111202238A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102077936B (zh) | 一种糖尿病患者专用的海洋特膳食品 | |
| CN104542865B (zh) | 一种基于甘薯的功能性糕点及其制备方法 | |
| CN102077934B (zh) | 一种高血压患者专用的海洋特膳食品 | |
| CN102077940B (zh) | 一种冠心病患者专用的海洋特膳食品 | |
| CN102077939B (zh) | 一种肥胖人士专用的海洋特膳食品 | |
| CN102077945B (zh) | 一种人流、产后专用的海洋特膳食品 | |
| CN102077938B (zh) | 一种肝损伤患者专用的海洋特膳食品 | |
| WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
| CN102077937B (zh) | 一种中青年女士专用的海洋特膳食品 | |
| CN107455698A (zh) | 一种用于促进智力发育的海洋多肽特膳食品 | |
| CN108618126A (zh) | 一种中药复方减肥特殊膳食食品及其制备方法 | |
| CN105815514A (zh) | 藜麦减肥奶茶 | |
| CN102077944B (zh) | 一种前列腺患者专用的海洋特膳食品 | |
| CN108095072A (zh) | 供长期卧床及肌肉衰减综合征人群食用短肽特膳食品配方 | |
| CN105249175A (zh) | 一种调理饮食疾病的全面营养粉及其制备方法 | |
| CN106036898A (zh) | 一种具有抗疲劳功效的组合物及制备方法和用途 | |
| CN107373487A (zh) | 一种甘氨酸亚铁冲剂 | |
| CN102526360B (zh) | 一种具有辅助减肥功能的保健品 | |
| CN100502694C (zh) | 一种用于减肥和降血脂的海洋功能食品 | |
| CN105707378A (zh) | 黑青稞瘦身咖啡 | |
| CN102552574A (zh) | 一种减肥功能的保健药物配方 | |
| CN112205557A (zh) | 一种降血脂药食物质固体饮料及其制备方法 | |
| CN109303115A (zh) | 生酮减肥代餐奶昔 | |
| JP3433917B2 (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
| CN111202238A (zh) | 一种具有降血脂功能的保健品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200529 |
|
| WD01 | Invention patent application deemed withdrawn after publication |